Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $6.8750.

Several research firms recently weighed in on SRTS. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $3.07 on Friday. Sensus Healthcare has a fifty-two week low of $2.66 and a fifty-two week high of $5.92. The company has a market capitalization of $50.53 million, a PE ratio of -6.53 and a beta of 1.09. The stock has a fifty day moving average of $3.19 and a two-hundred day moving average of $3.93.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

Hedge Funds Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of SRTS. Opes Wealth Management LLC purchased a new position in Sensus Healthcare during the third quarter worth approximately $50,000. XTX Topco Ltd purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $77,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $79,000. Mindset Wealth Management LLC grew its stake in shares of Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after buying an additional 11,000 shares during the period. Finally, Ingalls & Snyder LLC acquired a new stake in shares of Sensus Healthcare during the 4th quarter worth $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.